Clinical Trial Update: Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma [Phase 2]

View source ↗

Summary

This update reports safety, immune responses, and tumor responses from a Phase 2 trial of MKC1106-MT in Stage III/Stage IV melanoma, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MKC1106-MT

Snippet

Sponsor: Mannkind Corporation | Conditions: Stage III Melanoma, Stage IV Melanoma | Phase 2 | Status: TERMINATED